IL15 and non-Hodgkin lymphoma: In a phase 1 trial of patients with relapsed or refractory non-Hodgkin lymphoma (NCT03019666), the adoptive transfer of NK cells cultured with IL-15 and nicotinamide in combination with rituximab showed a complete response in 13 of 19 patients, with NK cells detected 14 days post-infusion [59].